Biogen pushes back its timeline on the big aducanumab FDA filing as Covid-19 slows work — shares wilt
You can scratch off an early 2020 aducanumab filing from your list of Biogen catalysts.
The big biotech $BIIB reported Wednesday morning that it is “making good progress” toward an FDA filing of the Alzheimer’s drug, which is now planned for Q3. And the stock tanked ahead of the bell, dropping 10% as analysts repeatedly probed the aducanumab delay and studied the Q1 numbers, which included a 9% hike in Spinraza revenue as well as signs of trouble for their overall pipeline schedule as the pandemic maelstrom afflicts R&D.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.